33
total announcements
SAIPARENT.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹2,134 Cr
P/E (TTM)
166.6
EPS (TTM)
₹2.90
52W Low
₹400.00
52W High
₹706.00
Dividend Yield
0.00%
Price / Book
3.2
Debt / Equity
49.1
Revenue (TTM)
₹526 Cr
Gross Margin
37.94%
Operating Margin
8.62%
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the details of securities dematerialized during the quarter ended 30th September, 2026.
Sai Parenterals Limited
Sai Parenterals Limited has completed the acquisition of 60% equity stake in Prathyak Laboratories Private Limited, an operating research and development centre, for Rs. 15 crore. The acquisition replaces the greenfield research centre the Company had originally intended to build and will support the Company's injectable programme directly.
Sai Parenterals Limited
Sai Parenterals Limited has received a monitoring agency report for the quarter ended 30 June 2026, highlighting deviations from the objects of the IPO. The report notes deviations in the utilization of proceeds for capacity expansion, repayment of borrowings, general corporate purposes, and issue-related expenses.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about the schedule of an analyst/institutional investor meeting on October 14th, 2026, in Hyderabad, where company officials will discuss publicly available information with investors and analysts.
Sai Parenterals Limited
Sai Parenterals Limited has closed its trading window for dealing in its securities from 01st October, 2026, until 48 hours after the declaration of its un-audited financial results for the quarter and half year ended 30th September, 2026.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about Change in Company Secretary/Compliance Officer. Ms. Shivali Aggarwal has resigned as Company Secretary & Compliance Officer, and Mr. Ashwani Singh Bisht has been appointed as the new Company Secretary & Compliance Officer, effective 30th September 2026.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026, where the Board considered and approved the resignation of Ms. Shivali Aggarwal as Company Secretary & Compliance Officer, and the appointment of Mr. Ashwani Singh Bisht and Mr. Arvind Gannimitta as new Company Secretary & Compliance Officer and Chief Operating Officer respectively.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about Shareholders meeting. The 25th Annual General Meeting (AGM) of the company was held on 10.09.2026 through Video Conferencing. The meeting commenced at 11:14 A.M. and concluded at 12:05 PM. The Chairman extended a warm welcome to all members, auditors and other invitees who joined the meeting through VC.
Sai Parenterals Limited
Sai Parenterals Limited, an integrated CDMO and branded generics enterprise, has announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The renewal carries an expanded product portfolio, a long agreement tenure, and a higher agreement value, and is projected at AUD 30 million over a three-year term.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about bagging/receiving of orders/contracts. The company's subsidiary Noumed Pharmaceuticals Pty Limited has renewed its long-term OTC Medicines Supply Agreement with one of Australia's leading pharmacy chains. The agreement is for a 3-year term with a projected value of AUD 30 Million, aggregating to approximately Rs. 204 Crores.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about a scheduled Analyst/Institutional Investor Meeting on August 31, 2026, in Mumbai, where the management will interact with investors and discuss publicly available information.
Sai Parenterals Limited
Sai Parenterals Limited has announced the notice of its 25th Annual General Meeting (AGM) for the financial year 2025-26, to be held on September 10, 2026, through video conferencing.
Sai Parenterals Limited
Sai Parenterals Limited has submitted a copy of newspaper publication for a change and variation in the objects of utilization of the Initial Public Offering (IPO) proceeds.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about Intimation of Book closure and cutoff date for the 25th Annual General Meeting.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 10, 2026.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about the transcript of the earnings conference call held on 12th August, 2026. The company's Q1 FY '27 earnings conference call was conducted on 12th August 2026 at 02:30 p.m. (IST). The transcript is available on the company's website and on the stock exchange's website. The company's consolidated total revenue for the quarter stood at Rs. 182 crores against Rs. 201 crores in the Q4 FY '26. Gross profit was Rs. 76 crores at a gross margin of 41.8%. EBITDA stood at Rs. 27 crores at a margin of 14.9% and profit after tax at Rs. 8 crores at a margin of 4.3%. The company's order flow has always been weighted towards the second half, with the 4th Quarter historically their strongest. Gross margin improved to 41.8% from 38.1% in the preceding quarter, an expansion of 370 basis points. The company has approved a proposed variation in the objects of the IPO issue, redeploying Rs. 101.85 crores originally earmarked for capacity expansion and upgradation of manufacturing facilities and research and development center.
Sai Parenterals Limited
Sai Parenterals Limited has informed the Exchange about the audio recording of the earnings call held on 12th August, 2026, available on their website.
Sai Parenterals Limited
Sai Parenterals Limited has made an investor presentation for its financial results for the quarter ended June 30, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Sai Parenterals Limited
Sai Parenterals Limited has announced its un-audited financial results for the quarter ended 30.06.2026, with revenue of Rs. 182.4 crore, gross profit of Rs. 76.2 crore, EBITDA of Rs. 27.3 crore, and PAT of Rs. 7.9 crore. The company has also announced a proposed variation in the utilisation of IPO proceeds and a new critical-care injectable facility acquisition.